share_log

Piper Sandler Maintains Overweight on TELA Bio, Lowers Price Target to $5

Benzinga ·  Nov 8 21:47  · Ratings

Piper Sandler analyst Matt O'Brien maintains TELA Bio (NASDAQ:TELA) with a Overweight and lowers the price target from $8 to $5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment